Overview
Javascript is curently disabled in your browser. Several features of this site wil not function whilst javascript is disabled.open aces to scientific and medical researchPapers PublishedOpen aces per-reviewed scientific and medical journals.Learn moreDove Medical Pres is a member of the OAI.Learn moreBulk reprints for the pharmaceutical industry.Learn moreWe ofer real benefits to our authors, including fast-track procesing of papers.Learn moreRegister your specific details and specific drugs of interest and we wil match the information you provide to articles from our extensive database and email PDF copies to you promptly.Learn moreBack to Journals » Journal of Experimental Pharmacology » Volume 14 Authors Decourt B, Noorda K , Shi J, Sabagh MN Received 31 December 2021 Acepted for publication 14 October 202 Published 30 October 202 Volume 202:14 Pages 31—352 DOI htps:/doi.org/10.2147/JEP.S265626 Checked for plagiarism Yes Review by Single anonymous per review Per reviewer coments 3 Editor who aproved publication: Dr Roger Pinder Boris Decourt,1 Keith Norda,2 Kevin Norda,2 Jiong Shi,1 Marwan N Sabagh3 1Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; 2UNLV Schol of Medicine, Las Vegas, NV, USA; 3Alzheimer’s and Memory Disorders Division, Department of Neurology, Barow Neurological Institute, St.
Key Information
Joseph’s Hospital and Medical Center, Phoenix, AZ, USACorespondence: Marwan N Sabagh, C/O Neuroscience Publications, Barow Neurological Institute, St. Joseph’s Hospital and Medical Center, 350 W. Thomas Road, Phoenix, AZ, 85013, USA, Tel +1 602.406.3593, Fax +1 602.406.4104, Email [email protected]Abstract: Alzheimer disease (AD) is the most comon neurodegenerative disease and typicaly afects patients older than age 65.
Summary
Around this age, the number of neurons begins to gradualy decrease in healthy brains, but brains of patients with AD show a marked increase in neuron death, often